Friday, 24 Jan 2020

You are here

Health Hazards of Fructose and Soda

The health consequences of fructose-containing sugars, sucrose and high fructose corn syrup, found in sugar-sweetened beverages and foods, may be numerous and include obesity, type 2 diabetes, gout and cardiovascular disease.

Researchers from Harvard have reviewed and summarized the epidemiological and clinical trial evidence that added sugars, especially sugar-sweetened beverages, may alter the risk of obesity, diabetes, and cardiovascular disease

Recent epidemiological studies and meta-analyses from these studies reveals that consuming one or two servings a day has been linked to

  • as high as a 26 percent greater risk of developing type 2 diabetes
  • a 35 percent greater risk of heart attack or fatal heart disease and
  • a 16 percent increased risk of stroke

Glucose is readily absorbed from the gastrointestinal tract into the blood and transported by insulin into the body's cells to be used as fuel. Fructose, on the other hand, is metabolized in the liver where it can be converted to fatty compounds called triglycerides, which may lead to fatty liver disease and insulin resistance, key risk factors for developing diabetes and cardiovascular disease. Overconsumption of fructose can also lead to too much uric acid in the blood, which is associated with a greater risk of gout.

This review also discusses strategies to reduce intake of fructose-containing beverages. (Citation source: http://buff.ly/1hb3ADC)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.